MetaCap

Keros Therapeutics (KROS) vs Vanda Pharmaceuticals (VNDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vanda Pharmaceuticals (VNDA) has outperformed Keros Therapeutics (KROS) over the past year, losing 28.2% versus a loss of 36.3%. Over five years, VNDA leads with a -79.2% price change compared with -80.2% for KROS. Keros Therapeutics is the larger company by market cap ($217.4 million vs $208.3 million), about 1.0 times the size.

Keros Therapeutics converts more of its revenue into profit, with a net margin of 35.7% versus -102.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KROS-36.29%VNDA-28.23%
+106%+26%-55%
Nov 21, 20251 yearNov 20, 2026
KROS-81.48%VNDA-79.69%
+23%-33%-89%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KROS versus VNDA key metrics
MetricKROSVNDA
Share price$11.08$3.45
Market cap$217.44M$208.32M
1-day change-2.72%-6.13%
YTD return-45.58%-60.94%
1-year return-36.29%-28.23%
5-year return-80.25%-79.18%
Forward P/E—17.22
EPS (TTM)$-2.32$-4.62
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$243.86M$216.10M
Revenue growth (YoY)—+8.72%
Net income (latest FY)$87.01M$-220.47M
Gross margin—93.96%
Operating margin27.71%-69.95%
Net margin35.68%-102.02%
52-week high$22.55$9.94
52-week low$8.98$3.42
Distance from 52-week high-50.86%-65.34%
Analyst consensusbuynone
Avg. price target upside+78.97%+233.82%
Average volume196.50K1.06M
Shares outstanding19.62M60.47M
Employees87533
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Keros Therapeutics is more profitable, keeping 35.7 cents of every revenue dollar as net income versus -102.0 cents for Vanda Pharmaceuticals.

About Keros Therapeutics

KROS stock →

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

About Vanda Pharmaceuticals

VNDA stock →

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.

Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees

KROS vs VNDA FAQ

Which is bigger, Keros Therapeutics or Vanda Pharmaceuticals?

Keros Therapeutics (KROS) is larger, with a market capitalization of $217.44M compared with $208.32M for Vanda Pharmaceuticals (VNDA).

Which stock has performed better over the past year, KROS or VNDA?

VNDA returned -28.23% over the past 12 months, compared with -36.29% for KROS (price return, excluding dividends). Past performance does not predict future results.

Are Keros Therapeutics and Vanda Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons